Thymulin vs Pancragen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Thymulin is a nonapeptide hormone produced exclusively by the thymic epithelium. It requires zinc for biological activity and plays a critical role in T-lymphocyte maturation, differentiation, and immune regulation. Thymulin levels decline dramatically with age, contributing to immunosenescence.
- Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
- Half-Life
- ~30 minutes active half-life
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 20-30 mcg
- 10 mg per day
- Frequency
- 10 days per month (Khavinson protocol)
- Daily for 10–30 days
- Key Benefits
- Enhances T-cell maturation and differentiation
- Boosts NK cell cytotoxic activity
- Reduces inflammatory cytokine production (TNF-α, IL-1)
- Anti-nociceptive (pain-reducing) properties
- Restores age-related immune decline
- Anti-inflammatory via serotonin pathway modulation
- Supports pancreatic beta cell function and insulin secretion
- May improve glucose metabolism in early metabolic dysfunction
- Protective effects on exocrine pancreatic tissue
- Anti-aging effects on pancreatic cells
- Potential support in type 2 diabetes management alongside standard care
- Reduces pancreatic cellular apoptosis from metabolic stress
- Complementary to GLP-1 agonists in metabolic protocols
- Side Effects
- Injection site reactions
- Mild fatigue initially as immune system activates
- Generally well tolerated
- Mild injection site reactions
- No significant hypoglycemic events reported at standard doses as monotherapy
- Stacks With
- —
- —